{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T12:38:38Z","timestamp":1781354318699,"version":"3.54.1"},"reference-count":45,"publisher":"BMJ","issue":"8","funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2018,7,12]]},"published-print":{"date-parts":[[2018,8]]},"abstract":"<jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>North America is amid an opioid use epidemic. Opioid agonist treatment (OAT) effectively reduces extramedical opioid use and related harms. As with all pharmacological treatments, there are risks associated with OAT, including fatal overdose. There is a need to better understand risk for adverse outcomes during and after OAT, and for innovative approaches to identifying people at greatest risk of adverse outcomes. The Opioid Agonist Treatment and Safety study aims to address these questions so as to inform the expansion of OAT in the USA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and analysis<\/jats:title>\n                  <jats:p>This is a retrospective cohort study using linked, routinely collected health data for all people seeking OAT in New South Wales, Australia, between 2001 and 2017. Linked data include hospitalisation, emergency department presentation, mental health diagnoses, incarceration and mortality. We will use standard regression techniques to model the magnitude and risk factors for adverse outcomes (eg, mortality, unplanned hospitalisation and emergency department presentation, and unplanned treatment cessation) during and after OAT, and machine learning approaches to develop a risk-prediction model.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Ethics and dissemination<\/jats:title>\n                  <jats:p>This study has been approved by the Population and Health Services Research Ethics Committee (2018HRE0205). Results will be reported in accordance with the REporting of studies Conducted using Observational Routinely-collected health Data statement.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjopen-2018-025204","type":"journal-article","created":{"date-parts":[[2018,8,6]],"date-time":"2018-08-06T01:56:01Z","timestamp":1533520561000},"page":"e025204","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":26,"title":["Using routinely collected data to understand and predict adverse outcomes in opioid agonist treatment: Protocol for the Opioid Agonist Treatment Safety (OATS) Study"],"prefix":"10.1136","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5602-4963","authenticated-orcid":false,"given":"Sarah","family":"Larney","sequence":"first","affiliation":[{"name":"National Drug and Alcohol Research Centre, University of New South Wales, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Hickman","sequence":"additional","affiliation":[{"name":"Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A","family":"Fiellin","sequence":"additional","affiliation":[{"name":"Schools of Medicine and Public Health, Yale University, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Dobbins","sequence":"additional","affiliation":[{"name":"National Drug and Alcohol Research Centre, University of New South Wales, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Nielsen","sequence":"additional","affiliation":[{"name":"Monash Addiction Research Centre, Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola R","family":"Jones","sequence":"additional","affiliation":[{"name":"National Drug and Alcohol Research Centre, University of New South Wales, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard P","family":"Mattick","sequence":"additional","affiliation":[{"name":"National Drug and Alcohol Research Centre, University of New South Wales, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Ali","sequence":"additional","affiliation":[{"name":"Medical Sciences, University of Adelaide, Adelaide, South Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louisa","family":"Degenhardt","sequence":"additional","affiliation":[{"name":"National Drug and Alcohol Research Centre, University of New South Wales, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,8,5]]},"reference":[{"key":"2025101815154801000_8.8.e025204.1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6712a1"},{"key":"2025101815154801000_8.8.e025204.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2017.07.018"},{"key":"2025101815154801000_8.8.e025204.3","unstructured":"British Columbia Coroners Service. Illicit Drug Overdose Deaths in BC. Vancouver: British Columbia Coroners Service, 2018."},{"key":"2025101815154801000_8.8.e025204.4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.11859"},{"key":"2025101815154801000_8.8.e025204.5","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3989"},{"key":"2025101815154801000_8.8.e025204.6","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/pds.4369","article-title":"Trends in opioid utilisation in Australia, 2006-2015: Insights from multiple metrics","volume":"27","author":"Karanges","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025101815154801000_8.8.e025204.7","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1001\/jamapsychiatry.2017.4432","article-title":"Rapid change in fentanyl prevalence in a community-based, high-risk sample","volume":"75","author":"Jones","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"2025101815154801000_8.8.e025204.8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.2844"},{"key":"2025101815154801000_8.8.e025204.9","first-page":"443","article-title":"Community outbreak of hiv infection linked to injection drug use of oxymorphone--Indiana, 2015","volume":"64","author":"Conrad","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2025101815154801000_8.8.e025204.10","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2014.302142"},{"key":"2025101815154801000_8.8.e025204.11","first-page":"358","article-title":"Hepatitis C virus infections among young adults - rural Wisconsin, 2010","volume":"61","author":"Stanley","year":"2012","journal-title":"Morbidity and Mortality Weekly Report"},{"key":"2025101815154801000_8.8.e025204.12","first-page":"538","article-title":"Hepatitis C virus infection among adolescents and young adults - Massachusetts, 2002-2009","volume":"60","author":"Onofrey","year":"2011","journal-title":"Morbidity and Mortality Weekly Report"},{"key":"2025101815154801000_8.8.e025204.13","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa1515195","article-title":"HIV infection linked to injection use of oxymorphone in Indiana, 2014-2015","volume":"375","author":"Peters","year":"2016","journal-title":"N Engl J Med"},{"key":"2025101815154801000_8.8.e025204.14","unstructured":"The Council of Economic Advisers. The underestimated cost of the opioid crisis. Washington DC: Executive Office of the President of the United States, 2017."},{"key":"2025101815154801000_8.8.e025204.15","unstructured":"World Health Organization. Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. Geneva: World Health Organization, 2009."},{"key":"2025101815154801000_8.8.e025204.16","doi-asserted-by":"crossref","unstructured":"Nielsen S , Larance B , Degenhardt L , et al . Opioid agonist treatment for pharmaceutical opioid dependent people. Cochrane Database Syst Rev 2016;2016;172. Art. No. CD011117.doi:10.1002\/14651858.CD011117.pub2","DOI":"10.1002\/14651858.CD011117.pub2"},{"key":"2025101815154801000_8.8.e025204.17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2010.03140.x"},{"key":"2025101815154801000_8.8.e025204.18","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/add.14012","article-title":"Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis","volume":"113","author":"Platt","year":"2018","journal-title":"Addiction"},{"key":"2025101815154801000_8.8.e025204.19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e5945"},{"key":"2025101815154801000_8.8.e025204.20","doi-asserted-by":"crossref","unstructured":"Kendall CE , Boucher LM , Mark AE , et al . A cohort study examining emergency department visits and hospital admissions among people who use drugs in Ottawa, Canada. Harm Reduction Journal 2017;14(1.","DOI":"10.1186\/s12954-017-0169-7"},{"key":"2025101815154801000_8.8.e025204.21","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jsat.2017.12.003","article-title":"Associations between pharmacotherapy for opioid dependence and clinical and criminal justice outcomes among adults with co-occurring serious mental illness","volume":"86","author":"Robertson","year":"2018","journal-title":"J Subst Abuse Treat"},{"key":"2025101815154801000_8.8.e025204.22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jsat.2016.05.002","article-title":"Impact of medication-assisted treatment for opioid addiction on medicaid expenditures and health services utilization rates in Vermont","volume":"67","author":"Mohlman","year":"2016","journal-title":"J Subst Abuse Treat"},{"key":"2025101815154801000_8.8.e025204.23","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.drugalcdep.2014.09.007","article-title":"Dynamics in the costs of criminality among opioid dependent individuals","volume":"144","author":"Krebs","year":"2014","journal-title":"Drug Alcohol Depend"},{"key":"2025101815154801000_8.8.e025204.24","doi-asserted-by":"publisher","DOI":"10.1080\/10550880902772373"},{"key":"2025101815154801000_8.8.e025204.25","doi-asserted-by":"crossref","unstructured":"Russolillo A , Moniruzzaman A , McCandless LC , et al . Associations between methadone maintenance treatment and crime: a 17-year longitudinal cohort study of Canadian provincial offenders. Addiction 2018;113.doi:10.1111\/add.14059","DOI":"10.1111\/add.14059"},{"key":"2025101815154801000_8.8.e025204.26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j1550"},{"key":"2025101815154801000_8.8.e025204.27","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S2215-0366(15)00366-1","article-title":"Mortality risk of opioid substitution therapy with methadone versus buprenorphine: a retrospective cohort study","volume":"2","author":"Kimber","year":"2015","journal-title":"Lancet Psychiatry"},{"key":"2025101815154801000_8.8.e025204.28","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1111\/add.14188","article-title":"The impact of buprenorphine and methadone on mortality: a primary care cohort study in the United Kingdom","volume":"113","author":"Hickman","year":"2018","journal-title":"Addiction"},{"key":"2025101815154801000_8.8.e025204.29","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/j.1360-0443.2011.03745.x","article-title":"An increased risk of motor vehicle accidents after prescription of methadone","volume":"107","author":"Bramness","year":"2012","journal-title":"Addiction"},{"key":"2025101815154801000_8.8.e025204.30","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1111\/add.13013","article-title":"Arrhythmia associated with buprenorphine and methadone reported to the food and drug administration","volume":"110","author":"Kao","year":"2015","journal-title":"Addiction"},{"key":"2025101815154801000_8.8.e025204.31","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4637.2010.00877.x"},{"key":"2025101815154801000_8.8.e025204.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2011.07.019"},{"key":"2025101815154801000_8.8.e025204.33","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/dar.12344","article-title":"Diversion and injection of buprenorphine-naloxone film two years post-introduction in Australia","volume":"35","author":"Larance","year":"2016","journal-title":"Drug Alcohol Rev"},{"key":"2025101815154801000_8.8.e025204.34","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000166"},{"key":"2025101815154801000_8.8.e025204.35","unstructured":"Center for Substance Abuse Treatment. Medication-assisted treatment for opioid addiction in Opioid Treatment Programs. Treatment Improvement Protocol (TIP) Series 43. Rockville MD: Substance Abuse and Mental Health Services Administration, 2005."},{"key":"2025101815154801000_8.8.e025204.36","unstructured":"Center for Substance Abuse Treatment. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. Treatment Improvement Protocol (TIP) series 40. Rockville MD: Substance Abuse and Mental Health Services Administration, 2004."},{"key":"2025101815154801000_8.8.e025204.37","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/jamapsychiatry.2014.1754","article-title":"Predicting suicides after psychiatric hospitalization in US army soldiers: The Army Study to Assess Risk and Resilience in Servicemembers (Army STARRS)","volume":"72","author":"Kessler","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"2025101815154801000_8.8.e025204.38","unstructured":"AIHW. National opioid pharmacotherapy statistics (NOPSAD) 2016. Canberra: Australian Institute of Health and Welfare, 2017."},{"key":"2025101815154801000_8.8.e025204.39","unstructured":"NSW Health Department. Opioid treatment program: clinical guidelines for methadone and buprenorphine treatment. Sydney: NSW Health Department, 2006."},{"key":"2025101815154801000_8.8.e025204.40","unstructured":"Ritter A , Chalmers J . Polygon: the many sides to the Australian opioid pharmacotherapy maintenance system. Canberra: Australian National Council on Drugs, 2009."},{"key":"2025101815154801000_8.8.e025204.41","doi-asserted-by":"publisher","DOI":"10.1177\/183335830803700208"},{"key":"2025101815154801000_8.8.e025204.42","doi-asserted-by":"publisher","DOI":"10.1023\/A:1010933404324"},{"key":"2025101815154801000_8.8.e025204.43","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-9868.2005.00503.x"},{"key":"2025101815154801000_8.8.e025204.44","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-9868.2005.00503.x"},{"key":"2025101815154801000_8.8.e025204.45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001885"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2018-025204","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T22:15:57Z","timestamp":1760825757000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2018-025204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":45,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2018,8,5]]},"published-print":{"date-parts":[[2018,8]]}},"alternative-id":["10.1136\/bmjopen-2018-025204"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2018-025204","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8]]}}}